Topical Formulation Based on Arnebia euchroma as a Novel Possible Efficient Treatment on Epidermolysis Bullosa Lesions: A Case Series of Fourteen Patients

Main Article Content

Amirsaleh Abdollahi
Rouzbeh Kadkhodaee
Armaghan Kazeminejad
Lotfollah Davoodi
Muhammadreza Oraee Karimi
Alireza Razavi
Sobhan Mohebbi Najmabad

Abstract

BACKGROUND: Epidermolysis bullosa (EB) is a skin fragility disorder that results in the disruption of the dermo-epidermal junction and painful blisters on the skin and mucous membranes. Currently, there is almost no definite treatment for EB patients.


AIM: This study aims to assess the effect of topical formulation based on Arnebia euchroma (AE) on lesions induced by EB.


MATERIALS AND METHODS: All patients with EB diseases treated with Hochobeh ointment (AE+Beewax+Olive oil) in 2022 at our dermatological clinic were included in the study. EB diseases were diagnosed based on the following criteria: (1) clinical features (2) histopathological findings (3) Linear depositions of IgG, IgA, IgM 4. salt-split skin (SSS) or other immune serological tests compatible with the diagnosis of EB disease. Hochobeh ointment and lotion treatment were initiated. Clinical evaluations were repeated 3 and 7 days after the treatment began, and photographs were taken to document the changes in clinical severity. EB Disease Activity and Scarring Index (EBDASI) and EB Quality of Life (EB-QoL) questionnaires were used to assess the severity of EB and the quality of life, respectively. All statistical analyses were performed using statistical package for the social sciences version 16.


RESULTS: Overall, fourteen patients were included. Improvement in clinical features, including reduction of infection and inflammation and improvement of wound healing, was observed. EBDASI and EB-QoL scores decreased significantly after treatment (91.5 ± 45.7 vs. 68.9 ± 43, p = 0.001; 24.6 ± 6.7 vs. 18 ± 5.2, p = 0.001, respectively).


CONCLUSION: Hochobeh ointment may be effective in treating EB skin and mucosal lesions.

Downloads

Download data is not yet available.

Plum Analytics

Article Details

How to Cite
1.
Abdollahi A, Kadkhodaee R, Kazeminejad Armaghan, Davoodi L, Karimi MO, Razavi A, Najmabad SM. Topical Formulation Based on Arnebia euchroma as a Novel Possible Efficient Treatment on Epidermolysis Bullosa Lesions: A Case Series of Fourteen Patients. SEE J Immunol [Internet]. 2023 Jul. 20 [cited 2024 May 20];6(1):56-61. Available from: https://seejim.eu/index.php/seejim/article/view/6035
Section
Clinical Immunology

References

Fine JD. Inherited epidermolysis bullosa. Orphanet J Rare Dis. 2010;5:12. http://doi.org/10.1186/1750-1172-5-12 PMid:20507631

Fine JD, Eady RA, Bauer EA, Bauer JW, Bruckner-Tuderman L, Heagerty A, et al. The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol. 2008;58(6):931-50. https://doi.org/10.1016/j.jaad.2008.02.004 PMid:18374450

Intong LR, Murrell DF. Inherited epidermolysis bullosa: New diagnostic criteria and classification. Clin Dermatol. 2012;30(1):70-7. shttps://doi.org/10.1016/j.clindermatol.2011.03.012 PMid:22137229

Fine JD. Epidemiology of inherited epidermolysis bullosa based on incidence and prevalence estimates from the national epidermolysis Bullosa registry. JAMA Dermatol. 2016;152(11):1231-8. https://doi.org/10.1001/jamadermatol.2016.2473 PMid:27463098

Farokhforghani S, Fatemi MJ, Ghanooni P, Asadpour F, Araghi S, Nouri A. Epidermolysis bullosa registry data in Iran. World J Plast Surg. 2021;10(3):99-103. shttps://doi.org/10.29252/wjps.10.3.99 PMid:34912673

Kho YC, Rhodes LM, Robertson SJ, Su J, Varigos G, Robertson I, et al. Epidemiology of epidermolysis bullosa in the antipodes: The Australasian Epidermolysis bullosa Registry with a focus on Herlitz junctional epidermolysis bullosa. Arch Dermatol. 2010;146(6):635-40. http://doi.org/10.1001/archdermatol.2010.109 PMid:20566927

Petrof G, Papanikolaou M, Martinez AE, Mellerio JE, McGrath JA, Bardhan A, et al. The epidemiology of epidermolysis bullosa in England and Wales: Data from the national epidermolysis bullosa database. Br J Dermatol. 2022;186(5):843-8. https://doi.org/10.1111/bjd.20958 PMid:34927719

Brandling-Bennett HA, Morel KD. Common wound colonizers in patients with epidermolysis bullosa. Pediatr Dermatol. 2010;27(1):25-8. https://doi.org/10.1111/j.1525-1470.2009.01070.x PMid:20199405

Fatima Q, Ahmed N, Siddiqui B, Rehman A, Haq I, Khan GM, et al. Enhanced antimicrobial activity of silver sulfadiazine cosmetotherapeutic nanolotion for burn infections. Cosmetics. 2022;9(5):93.

Liu X, Gan H, Hu C, Sun W, Zhu X, Meng Z, et al. Silver sulfadiazine nanosuspension-loaded thermosensitive hydrogel as a topical antibacterial agent. Int J Nanomedicine. 2019;14:289-300. https://doi.org/10.2147/IJN.S187918 PMid:30643407

Nasiri E, Hosseinimehr SJ, Azadbakht M, Akbari J, Enayati- Fard R, Azizi S, et al. The healing effect of Arnebia euchroma ointment versus silver sulfadiazine on burn wounds in rat. World J Plast Surg. 2015;4(2):134-44.

Ou YY, Jiang Y, Li H, Zhang YY, Lu Y, Chen DF. Polysaccharides from Arnebia euchroma ameliorated endotoxic fever and acute lung injury in rats through inhibiting complement system. Inflammation. 2017;40(1):275-84. https://doi.org/10.1007/s10753-016-0478-0 PMid:27913955

Kumar A, Shashni S, Kumar P, Pant D, Singh A, Verma RK. Phytochemical constituents, distributions and traditional usages of Arnebia euchroma: A review. J Ethnopharmacol. 2021;271:113896. https://doi.org/10.1016/j.jep.2021.113896 PMid:33524510

Jain R, Bhardwaj P, Pandey SS, Kumar S. Arnebia euchroma, a plant species of cold desert in the himalayas, harbors beneficial cultivable endophytes in roots and leaves. Front Microbiol. 2021;12:696667. https://doi.org/10.3389/fmicb.2021.696667 PMid:34335527

Pourani MR, Vahidnezhad H, Mansouri P, Youssefian L, Rakhshan A, Hajimoradi B, et al. Losartan treatment improves recessive dystrophic epidermolysis bullosa: A case series. Dermatol Ther. 2022;35(7):e15515. http://doi.org/10.1111/dth.15515 PMid:35420725

Lamberts A, Euverman HI, Terra JB, Jonkman MF, Horváth B. Effectiveness and safety of rituximab in recalcitrant pemphigoid diseases. Front Immunol. 2018;9:248. https://doi.org/10.3389/fimmu.2018.00248 PMid:29520266

Sindici E, Astesano S, Fazio L, Dragonetti A, Pugliese M, Scully C, et al. Treatment of oral lesions in dystrophic epidermolysis bullosa: A case series of cord blood platelet gel and low-level laser therapy. Acta Derm Venereol. 2017;97(3):383-4. https://doi.org/10.2340/00015555-2512 PMid:27535037

Rogers CL, Gibson M, Kern JS, Martin LK, Robertson SJ, Daniel BS, et al. A comparison study of outcome measures for epidermolysis bullosa: Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) and the Instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa (iscorEB). JAAD Int. 2021;2:134-52. https://doi.org/10.1016/j.jdin.2020.12.007 PMid:34409361

Jain SV, Harris AG, Su JC, Orchard D, Warren LJ, McManus H, et al. The Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI): Grading disease severity and assessing responsiveness to clinical change in epidermolysis bullosa. J Eur Acad Dermatol Venereol. 2017;31(4):692-8. https://doi.org/10.1111/jdv.13953 PMid:27580431

Yazdanshenas A, Naderi E, Moravvej H, Heidari K, Faghankhani M, Vahidnezhad H, et al. The quality of life in epidermolysis bullosa (EB-QoL) questionnaire: Translation, cultural adaptation, and validation into the Farsi language. Int J Womens Dermatol. 2020;6(4):301-5. https://doi.org/10.1016/j.ijwd.2020.05.012 PMid:33015291

Frew JW, Martin LK, Nijsten T, Murrell DF. Quality of life evaluation in epidermolysis bullosa (EB) through the development of the QOLEB questionnaire: An EB-specific quality of life instrument. Br J Dermatol. 2009;161(6):1323-30. https://doi.org/10.1111/j.1365-2133.2009.09347.x PMid:19681875

Bardhan A, Bruckner-Tuderman L, Chapple IL, Fine JD, Harper N, Has C, et al. Epidermolysis bullosa. Nat Rev Dis Primers. 2020;6(1):78. https://doi.org/10.1038/s41572-020-0210-0 PMid:32973163

Kaith BS, Kaith NS, Chauhan NS. Anti-inflammatory effect of Arnebia euchroma root extracts in rats. J Ethnopharmacol. 1996;55(1):77-80. https://doi.org/10.1016/s0378-8741(96)01477-8 PMid:9121171

Liu H, Jin YS, Song Y, Yang XN, Yang XW, Geng DS, et al. Three new compounds from Arnebia euchroma. J Asian Nat Prod Res. 2010;12(4):286-92. https://doi.org/10.1080/10286021003743861 PMid:20419539

Shen CC, Syu WJ, Li SY, Lin CH, Lee GH, Sun CM. Antimicrobial activities of naphthazarins from Arnebia euchroma. J Nat Prod. 2002;65(12):1857-62. https://doi.org/10.1021/np010599w PMid:12502328

Atiyeh BS, Costagliola M, Hayek SN, Dibo SA. Effect of silver on burn wound infection control and healing: Review of the literature. Burns. 2007;33(2):139-48. https://doi.org/10.1016/j.burns.2006.06.010 PMid:17137719

Lu L, Qin A, Huang H, Zhou P, Zhang C, Liu N, et al. Shikonin extracted from medicinal Chinese herbs exerts anti-inflammatory effect via proteasome inhibition. Eur J Pharmacol. 2011;658(2-3):242-7. https://doi.org/10.1016/j.ejphar.2011.02.043 PMid:21392503

Sun WX, Liu Y, Zhou W, Li HW, Yang J, Chen ZB. Shikonin inhibits TNF-α production through suppressing PKC-NF-κB- dependent decrease of IL-10 in rheumatoid arthritis-like cell model. J Nat Med. 2017;71(2):349-56. https://doi.org/10.1007/s11418-016-1064-3 PMid:27943122

Yan Y, Furumura M, Gouya T, Iwanaga A, Teye K, Numata S, et al. Shikonin promotes skin cell proliferation and inhibits nuclear factor-κb translocation via proteasome inhibition in vitro. Chin Med J (Engl). 2015;128(16):2228-33. https://doi.org/10.4103/0366-6999.162512 PMid:26265618

Lee YS, Lee DY, Kim YB, Lee SW, Cha SW, Park HW, et al. The mechanism underlying the antibacterial activity of shikonin against methicillin-resistant Staphylococcus aureus. Evid Based Complement Alternat Med. 2015;2015:520578. https://doi.org/10.1155/2015/520578 PMid:26265924

Li J, Li S, Li H, Guo X, Guo D, Yang Y, et al. Antibiofilm activity of shikonin against Listeria monocytogenes and inhibition of key virulence factors. Food Control. 2021;120(1):107558. https://doi.org/10.1016/j.foodcont.2020.107558

Ahmad F, Bibi S, Kang M, Anees M, Ansar M, Alam MR, et al. Naphthoquinones from Handroanthus impetiginosus promote skin wound healing through Sirt3 regulation. Iran J Basic Med Sci. 2020;23(9):1139-45. https://doi.org/10.22038/ijbms.2020.43706.10275 PMid:32963735

Soltanian AR, Mehdibarzi D, Faghihzadeh S, Naseri M, Gerami A. Mixture of Arnebia euchroma and Matricaria chamomilla (Marhame-Mafasel) for pain relief of osteoarthritis of the knee - a two-treatment, two-period crossover trial. Arch Med Sci. 2010;6(6):950-5. https://doi.org/10.5114/aoms.2010.19307 PMid:22427772

Nasiri E, Hosseinimehr SJ, Hosseinzadeh AZ, Azadbakht M, Akbari J, Azadbakht M. The effects of Arnebia euchroma ointment on second- degree burn wounds: A randomized clinical trial. J Ethnopharmacol. 2016;189:107-16. https://doi.org/10.1016/j.jep.2016.05.029 PMid:27180881

Memarbashi E, Nasiri E, Etezadpour M, Hosseinimehr SJ. Effect of Arnebia euchroma ointment on pain and burning after hemorrhoidectomy: A randomized clinical trial. J Mazandaran Univ Med Sci. 2021;31(202):38-48.

Aliasl J, Khoshzaban F, Barikbin B, Naseri M, Kamalinejad M, Emadi F, et al. Comparing the healing effects of Arnebia euchroma Ointment with petrolatum on the ulcers caused by fractional CO laser: A single-blinded clinical trial. Iran Red Crescent Med J. 2014;16(10):e16239. https://doi.org/10.5812/ircmj.16239 PMid:25558382